Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Keytruda (pembrolizumab) immunotherapy
What Keytruda (pembrolizumab) immunotherapy is, how it unblocks T-cells to target cancer, and what clinical evidence shows. This guide outlines candidate suitability, biomarker testing, typical cycle schedules, approximate costs in Turkey compared with the UK, US and Germany, potential immune-related side effects, and how international patients manage treatment and follow-up care safely.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Keytruda (Pembrolizumab) Immunotherapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Keytruda (pembrolizumab) immunotherapy: what it is and how it works
Keytruda (pembrolizumab) immunotherapy is an advanced biological cancer treatment classified as an immune checkpoint inhibitor. Its active substance, pembrolizumab, is a humanised monoclonal antibody targeting the PD-1 (programmed cell death protein 1) receptor on immune T-cells. Under normal conditions, the PD-1 pathway acts as a checkpoint brake to prevent autoimmune damage to healthy tissues. Many cancer cells exploit this mechanism by displaying proteins that bind to PD-1, deactivating T-cells and evading immune detection. Pembrolizumab binds directly to the PD-1 receptor, blocking these inhibitory signals and allowing the body's cytotoxic T lymphocytes to recognise and attack malignant cells.
When considering Keytruda (pembrolizumab) immunotherapy in Turkey, patients access specialized oncology departments providing systemic biologic care at lower clinical and administrative costs than western private clinics. It is prescribed for approved indications including advanced melanoma, non-small cell lung cancer, kidney cancer, and urothelial carcinoma with confirmed biomarker expression. For wider cancer care pathways, see our guide to oncology treatments in Turkey.
How does Keytruda work against cancer cells?
Understanding how does Keytruda work begins with immune regulation. Normal T-cells carry surface receptors such as PD-1 that prevent autoimmune damage to healthy tissue. When PD-1 interacts with its ligands, PD-L1 and PD-L2, an inhibitory signal is transmitted into the T-cell, causing it to shut down. Malignant tumours frequently express dense PD-L1 shields on their cell surface, neutralising approaching immune cells.
Pembrolizumab binds to the PD-1 receptor with high affinity, physically obstructing PD-L1 and PD-L2 binding. With the checkpoint brake released, cytotoxic T-cells reactivate, multiply, and infiltrate tumour tissue to destroy malignant cells. Because this mechanism relies on restoring the host immune response rather than directly poisoning cells, it represents a foundational component of modern immunotherapy.
Does Keytruda actually work: what does the clinical evidence show?
Clinical efficacy is established by large international phase-III trials—including the KEYNOTE trial series—reviewed by the FDA, EMA, and the NHS National Institute for Health and Care Excellence (NICE). In advanced melanoma and metastatic non-small cell lung cancer, trials demonstrated marked improvements in progression-free survival and overall survival compared with traditional chemotherapy regimens.
However, Keytruda does not work for every patient or every tumour type. Response rates vary by cancer histology and biomarker status. In unselected patient groups, objective response rates range between 15% and 30%, but rise above 40% to 50% in tumours with high PD-L1 expression (tumour proportion score of 50% or higher) or microsatellite instability-high (MSI-H) status. While responding patients can achieve durable disease control for years, responsible oncology teams do not promise complete remission or certainty of response, as biological resistance can exist initially or develop over time.
Keytruda (pembrolizumab) immunotherapy cost in Turkey compared with the UK, US and Germany
Understanding Keytruda (pembrolizumab) immunotherapy cost involves looking at medication procurement and clinical day-unit fees. Because it is a specialised biologic manufactured under strict cold-chain standards, pembrolizumab cost represents the largest component of each treatment cycle. The figures in the table below outline approximate cost ranges per single infusion cycle across private healthcare systems.
| Country | Approximate cost per cycle | Typical inclusions |
|---|---|---|
| Turkey | €3,500 – €7,500 | Medication vial (200 mg), cleanroom reconstitution, day-unit care, oncologist review |
| United Kingdom | €6,000 – €11,000 | Private drug fee, pharmacy preparation, and specialist review (excludes NHS) |
| United States | €9,000 – €18,000 | Hospital facility fee and retail drug mark-up for uninsured patients |
| Germany | €5,500 – €10,000 | Hospital pharmacy compounding and standard oncology medical fees |
The overall Keytruda (pembrolizumab) immunotherapy price depends on dosing schedules (200 mg every three weeks or 400 mg every six weeks) and pre-infusion laboratory testing. In Turkey, hospital packages generally cover the imported medication, sterile compounding in laminar-flow cabinets, day-unit nursing, and doctor consultations. You can receive an itemised assessment through our free quote service.
Who is a good candidate for Keytruda, and who is not?
Candidate selection is determined by a medical oncologist based on tumour pathology and overall patient fitness. Favourable candidates typically present with:
- A confirmed histological diagnosis of an approved cancer (such as advanced melanoma, non-small cell lung cancer, renal cell, urothelial, or cervical carcinoma).
- Positive biomarker testing, such as high PD-L1 expression confirmed by immunohistochemistry (IHC) or confirmed MSI-H / dMMR tumour status.
- Good functional performance (ECOG score 0 or 1), indicating independence in daily self-care activities.
- Stable baseline liver, kidney, and bone marrow function.
Poor candidates include patients with active severe autoimmune diseases (such as systemic lupus or Crohn's disease), where checkpoint inhibitors risk provoking dangerous immune flares. Solid organ transplant recipients are also excluded due to severe risks of graft rejection. Patients with biomarker-negative tumours or rapid clinical deterioration are directed toward alternative oncological strategies.
How is Keytruda administered step by step?
Keytruda administration is an outpatient process requiring no surgical incisions or anaesthesia. A typical treatment day proceeds through four clinical stages:
- Pre-infusion blood work: Full blood counts, renal function, and liver enzymes are evaluated to verify that organ function safely permits treatment.
- Sterile pharmacy compounding: Hospital pharmacists reconstitute the liquid pembrolizumab concentrate in sterile conditions, diluting it in a saline intravenous infusion bag.
- Intravenous infusion: A cannula or portacath line is placed. The drug is infused over approximately 30 minutes through an in-line 0.2-micron filter while you rest in an infusion chair.
- Post-infusion observation: Nursing staff monitor vital signs for 30 to 60 minutes to ensure no immediate infusion-related allergic reactions occur before discharge.
Keytruda vs chemotherapy and targeted therapy: how do they compare?
Systemic cancer care encompasses multiple treatment modalities. Selecting the right approach depends on tumour genetics, staging, and previous treatments.
| Treatment modality | Primary mechanism | Best suited to | Typical clinical limits |
|---|---|---|---|
| Keytruda (Pembrolizumab) | PD-1 immune checkpoint blockade allowing T-cells to recognise tumour | PD-L1 positive or MSI-H / dMMR tumours across lung, skin, bladder and renal cancers | Takes time to establish response; risk of immune-related inflammatory toxicities |
| Standard chemotherapy | Cytotoxic destruction of rapidly dividing malignant cells | Rapid symptom reduction and tumours lacking actionable immune or genetic markers | Non-selective tissue impact; hair loss, nausea, reduced blood counts |
| Targeted therapy | Direct inhibition of specific oncogenic driver proteins (e.g. EGFR, ALK, BRAF) | Tumours with confirmed genetic mutations sensitive to small-molecule inhibitors | Secondary resistance mutations often emerge over time; limited to specific gene variants |
Unlike cytotoxic chemotherapy, pembrolizumab does not trigger complete hair loss or severe bone marrow suppression. Unlike targeted therapy, its action is not restricted to single driver mutations. In many advanced cancers, oncologists combine Keytruda with chemotherapy for enhanced therapeutic synergy.
Treatment results and scan monitoring: what can you realistically expect?
In medical oncology, treatment progress is assessed by radiological imaging and tumour markers rather than physical before-and-after photographs. Because immunotherapy relies on immune cellular proliferation, measurable tumour reduction develops gradually over several months.
Baseline scans are typically repeated after 9 to 12 weeks (three to four cycles). Scans evaluate tumour shrinkage, stabilization of disease, and metabolic activity. Importantly, a small subset of patients experiences pseudoprogression, where initial scans show enlarged lesions caused by an influx of inflammatory T-cells rather than true disease growth. Oncologists apply specialised immune-related response criteria (iRECIST) to confirm actual disease control and avoid stopping therapy prematurely.
Keytruda (pembrolizumab) immunotherapy recovery and trip planning in Turkey
Keytruda (pembrolizumab) immunotherapy recovery differs fundamentally from surgical healing. Most patients experience only mild fatigue or temporary muscle aches for 24 to 48 hours following an infusion. You can generally walk, eat normally, and undertake gentle activities immediately.
International patients planning treatment in Turkey follow a structured schedule:
- Initial cycle (5 to 7 days): Allows time for oncologist consultation, pathology review, baseline blood and imaging checks, infusion administration, and 48 hours of observation.
- Subsequent cycles (2 to 3 days): Maintenance infusions every three or six weeks require only short visits for blood tests and day-unit administration.
- Travel precautions: Stay well hydrated, walk during flights to reduce clotting risks, and carry your oncologist's medical summary.
Organising Keytruda (pembrolizumab) immunotherapy Turkey gives overseas patients access to coordinated oncological care with convenient scheduling between international travel dates.
How to choose an oncology centre in Turkey and questions to ask
Selecting a hospital for cancer therapy requires careful verification. Choose tertiary hospitals accredited by Joint Commission International (JCI) with dedicated cancer centres, comprehensive pathology laboratories, and 24-hour intensive care support. Verify that the pharmacy maintains certified cold-chain refrigeration (2°C to 8°C) for monoclonal antibody storage. To understand coordination steps, review how it works before planning your journey.
Be alert to red flags. Never engage with clinics that claim guaranteed cures, dismiss the risk of immune toxicities, or demand un-itemised upfront cash deposits before an oncologist reviews your medical files. Before committing to treatment, ask prospective clinics:
- Will a multidisciplinary tumour board review my pathology and biomarker results before treatment?
- Does the written cycle price include drug compounding, day-unit facility charges, and physician fees?
- What specific protocol does the hospital use to manage acute immune complications like pneumonitis?
- How will the clinical team communicate test results and treatment summaries to my doctor at home?
Hospitals with Oncology in Turkey
Frequently asked questions
Keytruda is a prescription immunotherapy drug containing the monoclonal antibody pembrolizumab. It works by blocking the PD-1 pathway on immune T-cells, preventing cancer cells from hiding from your immune defence. It is used to treat specific advanced cancers, including melanoma, non-small cell lung cancer, bladder cancer and tumours showing microsatellite instability.
Clinical trials and international regulatory bodies confirm that Keytruda significantly improves survival and disease control in selected patients, particularly those whose tumours express high levels of the PD-L1 biomarker. However, response rates vary across cancer types, and it does not work for every patient. Your oncologist will test your tissue to assess likely benefit.
The approximate cost of Keytruda in Turkey ranges from €3,500 to €7,500 per cycle, depending on whether you receive 200 mg every three weeks or 400 mg every six weeks. This price generally includes the imported medication, compounding and outpatient day-unit administration, but individual hospital quotes confirm exact fees based on your prescription.
Unlike cosmetic procedures, results are measured through CT, MRI or PET imaging rather than appearance. Successful treatment shows tumour shrinkage or stable disease over several months. In some cases, tumours may temporarily appear larger on initial scans due to immune cell infiltration—a phenomenon known as pseudoprogression—before objective shrinkage is observed.
Keytruda is typically administered every three or six weeks for up to two years, provided the tumour responds and side effects remain manageable. Treatment continues as long as clinical benefit persists without unacceptable toxicity. If the disease progresses or significant adverse events occur, your oncologist may adjust the schedule or switch therapies.
The intravenous infusion itself causes minimal discomfort, feeling similar to a routine intravenous drip or blood draw, and takes around thirty minutes in an outpatient day chair. Patients do not require anaesthesia. Mild fatigue, skin itching or low-grade nausea can develop later in the day, but severe immediate discomfort during administration is uncommon.
Common side effects include fatigue, mild nausea, skin rashes, joint pain and reduced appetite. Because pembrolizumab stimulates the immune system, it can also cause immune-related inflammation in organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis) or endocrine glands (thyroiditis). Routine blood tests and symptom checks monitor for these reactions between cycles.
Keytruda acts differently from chemotherapy. For patients with high PD-L1 biomarker expression, trials show pembrolizumab often provides longer disease control with fewer systemic toxicities than cytotoxic drugs. However, chemotherapy remains necessary when tumours lack immune targets or when rapid tumour shrinkage is required. Many treatment protocols combine both approaches for greater clinical impact.
For your first treatment, plan to stay in Turkey for five to seven days. This allows time for preliminary blood work, pathology confirmation, the day-unit infusion and forty-eight hours of post-treatment observation. For subsequent routine cycles, international patients typically require only two to three days in the country before flying home.
Most oncologists advise resting for twenty-four to forty-eight hours after an infusion before travelling. This window allows the clinical team to verify that you have not developed acute infusion reactions or fever. You should remain well hydrated, move your legs during travel and carry documentation of your emergency contact protocol.
Patient stories